Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
598 studies found for:    Open Studies | "Carcinoid Tumor"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Carcinoid Tumor"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Condition: Carcinoid Tumors
Interventions: Drug: Ramucirumab;   Drug: Somatostatin Analog
2 Recruiting A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
Condition: Carcinoid Tumors
Interventions: Drug: Lanreotide;   Drug: Placebo (for sunitinib);   Drug: Sunitinib
3 Available Expanded Access Protocol for Therapeutic Use of 177Lu-DOTA0-Tyr3-Octreotate in Patients With Inoperable, Somatostatin Receptor Positive, Midgut Carcinoid Tumors, Progressive Under Somatostatin Analogue Therapy
Condition: Midgut Carcinoid Tumor
Intervention: Drug: 177Lu-DOTA0-Tyr3-Octreotate
4 Recruiting Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
Condition: Carcinoid Tumor
Intervention: Drug: Ziv-aflibercept
5 Recruiting Natural History of Familial Carcinoid Tumor
Condition: Carcinoid
Intervention:
6 Recruiting SwissNET - a Registry for Neuroendocrine Tumours in Switzerland
Conditions: Neuroendocrine Tumors;   Carcinoid Tumor
Intervention:
7 Recruiting 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
Conditions: Neuroendocrine Tumors;   Carcinoid Tumors
Intervention: Device: 68Ga-DOTATOC PET
8 Recruiting Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Intervention: Drug: Lutetium-177 Octreotate
9 Not yet recruiting Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors
Condition: Small-intestine Neuroendocrine Tumors (Carcinoid Tumors)
Intervention: Biological: blood sample withdrawn
10 Recruiting Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Intervention: Drug: Recombinant anti-tumor and anti-virus protein for injection (Novaferon)
11 Recruiting Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study
Condition: Neuroendocrine Tumor
Intervention: Other: Videoconsultation
12 Recruiting Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Conditions: Carcinoid Tumors;   Pancreatic NET
Intervention: Drug: Ibrutinib
13 Recruiting Best Therapy for Patients With Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Intervention:
14 Recruiting A Pilot Study of Metformin Treatment in Patients With Well-differentiated Neuroendocrine Tumors
Condition: Well-differentiated Neuroendocrine Tumors
Intervention: Drug: Metformin
15 Recruiting Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Conditions: Carcinoid Tumor;   Metastatic Carcinoid Tumor;   Neuroendocrine Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Nintedanib;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment
16 Recruiting Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor
Condition: Neuroendocrine Tumor
Interventions: Other: Web-based tailored information and support system;   Other: Standard care
17 Recruiting Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Intervention: Other: 99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide
18 Recruiting A Study of Pembrolizumab in Patients With Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Intervention: Drug: Pembrolizumab
19 Recruiting Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Intervention: Drug: Lenvatinib
20 Recruiting Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Retrospective Analysis
Condition: Neuroendocrine Tumors
Intervention: Other: Metastasized intestinal NET

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.